← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Bessor Pharma, Llc
Framingham, MA
$6,305,417
Total funding
6
Grants
Funding over time
peak $1.3M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,305,417 · 6
By mechanism
R44$4,889,361 · 2
R43$1,196,926 · 3
R41$219,130 · 1
Investigators at Bessor Pharma, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Novel Target, New Therapy: Anti- Renalase Antibody for Tumors Resistant to PD-1Inhibitors$1,327,758
R44 · FY2021 · CA
Renalase: Development as an Innovative New Drug for Acute Pancreatitis$1,136,337
R44 · FY2020 · DK
Development of a novel renalase agonist for the treatment of acute pancreatitis$903,732
R44 · FY2025 · DK
Renalase: Development as an Innovative New Drug for Acute Pancreatitis$849,303
R44 · FY2019 · DK
Novel Target, New Therapy: Anti- Renalase Antibody for Tumors Resistant to PD-1Inhibitors$672,231
R44 · FY2022 · CA
Acute Pancreatitis: Renalase as a novel target and agonists as new therapy$300,000
R43 · FY2016 · DK
New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists$299,999
R43 · FY2023 · AI
Humanized Anti-Renalase Antibodies for Unresectable Melanoma$299,996
R43 · FY2018 · CA
New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists$296,931
R43 · FY2024 · AI
Therapeutic Utility of renalase and renalase peptides in cisplatin-mediated renal$219,130
R41 · FY2014 · CA